4B0G | Transferase | date | Jul 02, 2012 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
title | Complex Of Aurora-A Bound To An Imidazopyridine-Based Inhibi | ||||||||||||||
authors | M.Kosmopoulou, R.Bayliss | ||||||||||||||
compound | source | ||||||||||||||
Molecule: Aurora Kinase A Chain: A Fragment: Catalytic Domain, Residues 122-403 Synonym: Aurora 2, Auroraipl1-Related Kinase 1, Ark-1, Aur Related Kinase 1, Hark1, Breast Tumor-Amplified Kinase, Serinethreonine-Protein Kinase 15, Serinethreonine-Protei 6, Serinethreonine-Protein Kinase Aurora-A; Ec: 2.7.11.1 Engineered: Yes |
Organism_scientific: Homo Sapiens Organism_common: Human Organism_taxid: 9606 Expression_system: Escherichia Coli Expression_system_taxid: 562 | ||||||||||||||
symmetry | Space Group: P 41 21 2 |
| |||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | 2.50 Å | ||||||||||||
ligand | SO4, VEK | enzyme | Transferase E.C.2.7.11.1 BRENDA | ||||||||||||
Gene Ontology |
| ||||||||||||||
Primary reference | Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia., Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J, J Med Chem. 2012 Oct 25;55(20):8721-34. doi: 10.1021/jm300952s. Epub 2012 Oct 8. PMID:23043539 |
Data retrieval |
View 4B0G in 3D |
Visual 3D analysis of 4B0G |
Structure-derived information |
Sequence-derived information |
Other resources with information on 4B0G |
OCA© by Jaime Prilusky, 1996-2014,2022 Bioinformatics Unit Weizmann Institute of Science |